Palliative Medicine
May 19, 2026
Louis Plourde, Sue-Ling Chang, Olivia Nguyen et al.
1 citation
BACKGROUND: While the adoption of psilocybin-assisted therapy for existential distress offers promising support for patients with life-threatening illnesses, implementing this intervention into palliative care settings presents significant real-world challenges. AIM: To examine palliative care stakeholders' knowledge and attitudes regarding psilocybin-assisted therapy, and identify barriers and...
Palliative Medicine
January 30, 2026
James Downar, Julie Lapenskie, Koby Anderson et al.
Background: Psychological distress is a common problem near the end of life, for which we lack effective, timely and scalable treatments. No previous study has assessed whether microdose psilocybin can improve symptoms in this population. Aim: To determine whether microdose psilocybin is safe, feasible and potentially efficacious in a palliative setting. Design: Open label, single-arm clinical...
Palliative Medicine
December 18, 2025
Rita S. Matos, A. C. Silva, Licínio Rego et al.
1 citation
Background: Palliative Care is concerned with relieving suffering and improving the quality of life of patients and their families. Currently, questions arise about how to provide patients with good end-of-life care. There has been increasing interest in the beneficial effects of using psilocybin-assisted therapy in patients with severe chronic illnesses near the end of their lives and who...
Palliative Medicine
January 22, 2024
Louis Plourde, Sue-Ling Chang, Houman Farzin et al.
22 citations
Background: Internationally, there is a growing interest in the potential benefits of psilocybin-assisted therapy to treat existential distress at the end of life. However, the social acceptability of this therapy is not yet well known. Aim: This study assesses the social acceptability of the medical use of psilocybin to treat existential distress at the end of life. Design: An online survey...
Palliative Medicine
2001
A Fountain
The aim of the study was to determine the prevalence of visual hallucinations among hospice inpatients, and the prevalence of a number of possible associated risk factors. One hundred consecutive admissions to St. John's Hospice in Wirral were screened for visual hallucinations in a semi-structured interview. The prevalence of opioid administration, other drugs known to cause hallucinations,...